Why this matters?
1. Orchard Therapeutics Launch: Orchard Therapeutics has announced the U.S. commercial launch of Lenmeldy (atidarsagene autotemcel), a gene therapy for metachromatic leukodystrophy (MLD), with a wholesale acquisition cost of $4.25 million. #GeneTherapy #OrchardTherapeutics #Lenmeldy
2. Pricing Justification: The company justifies the high cost by highlighting the potential long-term impact of the treatment on healthcare utilization and the improved quality of life for patients and caregivers. #HealthcareCosts #PatientCare #QualityOfLife
3. ICER Assessment: The pricing was determined after a comprehensive health technology assessment by the Institute for Clinical and Economic Review (ICER), which set Lenmeldy’s health benefit price benchmark at up to $3.94 million. #ICER #CostEffectiveness #HealthEconomics
4. MLD Impact: Metachromatic leukodystrophy is a rare genetic metabolic disorder affecting one in every 100,000 live births, leading to severe cognitive and physical impairments. #RareDisease #MetabolicDisorder #MLD
5. Gene Therapy Benefits: Lenmeldy has shown significant improvement in survival and developmental milestones in treated children, positioning it as a paradigm-shifting medicine for early-onset MLD. #ClinicalTrials #TreatmentAdvancements #MedicalInnovation
6. Comparison with Other Therapies: Lenmeldy’s price continues the trend of high costs for gene therapies, with Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy priced at $2.2 million and bluebird bio’s Lyfgenia at $3.1 million. #GeneTherapyCosts #PharmaceuticalPricing #HealthcareIndustry
Two days after winning FDA approval, Orchard Therapeutics on Wednesday provided its U.S. launch plans for metachromatic leukodystrophy gene therapy Lenmeldy, which has a wholesale acquisition cost of $4.25 million for the one-time treatment.
#dfa #pharma #biospace
https://hubs.li/Q02q6shV0
Orchard Sets $4.25M US Price for Gene Therapy Lenmeldy on Heels of Approval | BioSpace
biospace.com